QUOTE AND NEWS
Motley Fool  Feb 6  Comment 
Array BioPharma racks up enormous gains to start the new year after announcing a steal of a deal. Find out whether or not there's more upside potential after its huge run.
FiercePharma  Feb 6  Comment 
India's Cipla argued before the Delhi High Court against the Novartis patent for its Onbrez (indacaterol) COPD drug, saying the patent need not be honored because the Swiss drugmaker was not working it in the country and has licensed it to Lupin...
The Hindu Business Line  Feb 4  Comment 
Drug firm Novartis India Ltd today reported a net loss of Rs 1.18 crore for the third quarter ended December 31, 2014.The company had posted a net profit of Rs 15.23 crore in the same perio...
FiercePharma  Feb 3  Comment 
SINGAPORE--Japan plans to temporarily suspend Novartis' pharma business in that country, according to media reports. The Ministry of Health, Labour and Welfare's order will last about 15 days and will cite repeated violations of failure to report...
Motley Fool  Feb 2  Comment 
Opthotech Corporation is researching a new therapy for wet-stage age-related macular degeneration that could have blockbuster potential.
Motley Fool  Jan 31  Comment 
Industry Focus zooms in on restructuring, new drugs, and possible threats for pharma giant Novartis.
FierceBiotech  Jan 29  Comment 
In this week's EuroBiotech Report, Belgian biotech ThromboGenics, having seen its stock price peak at €45 two years ago, has experienced a series of share slides, the latest of which was triggered by its partner Novartis. And more.
Motley Fool  Jan 29  Comment 
Hey Obama, how's this for precision medicine? Novartis will combine CAR-T and CRISPR/Cas9 technologies. Stem cells could get a boost, too.
FierceBiotech  Jan 28  Comment 
Novartis has admitted that sales of the vitreomacular adhesion drug it licensed from ThromboGenics have failed to live up to expectations. And while various theories have been put forward to explain the drug's relative lack of commercial success,...




 

Fuerralz? That's marvelously good to know.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki